ArticleAmerican journal of respiratory and critical care medicine2023
Phase 3 Open-Label Clinical Trial of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged 2-5 Years with Cystic Fibrosis and at Least One
Registry-linked trialOpen access · hybridAbstract read
In one paragraph
Article in American journal of respiratory and critical care medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07632768 (The Return of the Pancreas), which is not on this map. Cited by 67 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed, 3 pooled it
30.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Return of the Pancreas: Evaluating Impact of CFTR Modulators on Pancreatic Function
Who cites it
67 citing papers in PubMed, 3 syntheses or guidelines pooled it, 119 citations in OpenAlex.
- Pharmacokinetics of Ivacaftor, Tezacaftor, Elexacaftor, and Lumacaftor in Special Cystic Fibrosis Populations: A Systematic Review.Clinical pharmacokinetics · 2025Pooled it
- Use of elexacaftor+tezacaftor+ivacaftor in individuals with cystic fibrosis and at least one F508del allele: a systematic review and meta-analysis.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2024Pooled it
- Efficacy and safety profile of elexacaftor-tezacaftor-ivacaftor triple therapy on cystic fibrosis: a systematic review and single arm meta-analysis.Frontiers in pharmacology · 2023Pooled it
- Safety and efficacy of elexacaftor/tezacaftor/ivacaftor in adolescents and adults with cystic fibrosis and F508del-gating and F508del-residual function genotypes: results from an open-label extension study.Annals of the American Thoracic Society · 2026Trial
- Vanzacaftor-tezacaftor-deutivacaftor for children aged 6-11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial.The Lancet. Respiratory medicine · 2025Trial
- Adverse events during cystic fibrosis transmembrane conductance regulator modulator therapy in children with cystic fibrosis: an observational study.Pharmacological reports : PR · 2026Article
- Physiologically Based Pharmacokinetic Modeling of Elexacaftor-Tezacaftor-Ivacaftor in Adults and Pediatric People with Cystic Fibrosis: Exploring Brain Exposure and Neuropsychiatric Adverse Events.Clinical pharmacokinetics · 2026Article
- Long-term effectiveness and safety of cystic fibrosis transmembrane conductance regulator modulators and their impact on the lives of people with cystic fibrosis.American journal of respiratory and critical care medicine · 2026Article
- Residual disease activity in cystic fibrosis lung disease: implications for clinical management and research.American journal of respiratory and critical care medicine · 2026Review
- The dipeptidyl peptidase 1 inhibition landscape in bronchiectasis and its future direction.European respiratory review : an official journal of the European Respiratory Society · 2026Review
- Anti-inflammatory and phosphorylation effects of CFTR modulator triple therapy in cystic fibrosis.iScience · 2026Article
- DNA sequencing for microbial surveillance in cystic fibrosis airways: advances, challenges, and clinical translation.Clinical microbiology reviews · 2026Review
- Early CFTR modulation and clinical outcomes in preschool cystic fibrosis.Pediatric research · 2026Article
- Pediatric hepatic laboratory reporting with CFTR modulators: a FAERS pharmacovigilance study.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Effects of elexacaftor/tezacaftor/ivacaftor on the nasal microbial metagenome in cystic fibrosis.Microbiology spectrum · 2026Article
- Impact of Elexacaftor/Tezacaftor/Ivacaftor on Systemic Antibiotic Utilization in Pediatric Patients With Cystic Fibrosis.Pediatric pulmonology · 2026Article
- Targeted Therapy for Restoring CFTR Activity: From Experimental to Clinical Features.International journal of molecular sciences · 2026Review
- Cystic Fibrosis Newborn Screening: Cost Trajectory as a Marker to Improve Health Outcomes.Pediatric pulmonology · 2026Article
- Impact of Highly Effective CFTR Modulator Therapy on Physical Activity, Sleep, and Sinonasal Symptoms in Preschool Children with Cystic Fibrosis: A Prospective Single-Center Pilot Study.Advances in respiratory medicine · 2026Observational
- Impact of CFTR modulator concentrations on clinical response in cystic fibrosis.The European respiratory journal · 2026Observational
7 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
19 authors at 13 institutions in 5 countries.
Jennifer L GoralskiUniversity of North Carolina School of Medicine, Chapel Hill, North Carolina.
Jordana E HoppeUniversity of Colorado School of Medicine and Children's Hospital Colorado, Aurora, Colorado.
Marcus A MallDepartment of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.ORCID 0000-0002-4057-2199
Susanna A McColleyAnn & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Edward McKoneSt. Vincent's Hospital, Dublin, Ireland.ORCID 0000-0002-5455-8208
Bonnie RamseySeattle Children's Research Institute, Seattle, Washington.
Jonathan H RaymentUniversity of British Columbia and British Columbia Children's Hospital, Vancouver, British Columbia, Canada.
Phil RobinsonThe Royal Children's Hospital, Murdoch Children's Research Institute, Melbourne, Victoria, Australia.
Florian StehlingChildren's Hospital, University of Duisburg-Essen, Essen, Germany.
Jennifer L Taylor-CousarNational Jewish Health, Denver, Colorado.ORCID 0000-0002-5436-9722
Elizabeth TullisSt. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.
Neil AhluwaliaVertex Pharmaceuticals Inc., Boston, Massachusetts; and.
Anna ChinVertex Pharmaceuticals Inc., Boston, Massachusetts; and.
Chenghao ChuVertex Pharmaceuticals Inc., Boston, Massachusetts; and.
Mengdi LuVertex Pharmaceuticals Inc., Boston, Massachusetts; and.
Tao NiuVertex Pharmaceuticals Inc., Boston, Massachusetts; and.
Tanya WeinstockVertex Pharmaceuticals Inc., Boston, Massachusetts; and.
Felix RatjenUniversity of Toronto, Toronto, Ontario, Canada.
Margaret RosenfeldSeattle Children's Research Institute, Seattle, Washington.ORCID 0000-0002-8105-614X
Vertex Pharmaceuticals (United States) · USUniversity of Washington · USChildren's Hospital Colorado · USHumboldt-Universität zu Berlin · DENational Jewish Health · USNorthwestern University · USRoyal Children's Hospital · AUSt. Michael's Hospital · CASt. Vincent's University Hospital · IEUniversity of British Columbia · CAUniversity of Duisburg-Essen · DEUniversity of North Carolina at Chapel Hill · USUniversity of Toronto · CA
Funding
Translational Research Center to Expedite Novel Therapies in Cystic FibrosisP30DK089507 · NIDDK · SEATTLE CHILDREN'S HOSPITAL · PI Christopher Hooper Goss, Lucas R Hoffman · 2010 to 2026
$21.4MNIDDK NIH HHS P30 DK089507
Abstract
PubMed holds no abstract for this paper.
Indexed as
Cystic FibrosisAgedAllelesAminophenolsBenzodioxolesChildChloride Channel AgonistsChloridesCystic Fibrosis Transmembrane Conductance RegulatorHumansIndolesMutationPyrazolesPyridinesPyrrolidinesQuinolonesAminophenolsBenzodioxolesChloride Channel AgonistsChloridesCystic Fibrosis Transmembrane Conductance RegulatorelexacaftorIndolesivacaftorPyrazolesPyridinesPyrrolidinesQuinolonestezacaftorCFELXIVApreschool childrenTEZ
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
NCT07632768ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.